Another important example is the combination of BRAF and MEK inhibition with dabrafenib and trametinib or vemurafenib and cobimetinib for the treatment of melanoma harboring a BRAF V600E mutation [5,6,7]. This evidence concerns the gene BRAF and melanoma.